AZN•benzinga•
AstraZeneca Announced TAGRISSO (osimertinib) Demonstrated 5.5-year Median Disease-free Survival in the Adjuvant Treatment of Patients with EGFR-mutated Lung Cancer; Data Presented at ESMO 2022
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 11, 2022 by benzinga